Dr. Daniel Chai is Co-Founder and Executive Chairman of Milu Labs. Prior to founding the company, Dr. Chai was a healthcare investor with close to two decades of investment experience.

他目前是灯塔投资的管理合伙人。灯塔投资是一家在医疗保健公司进行孵化和投资的全球投资公司。他曾在几家领先的公司担任投资组合经理，领导着医疗保健投资团队，包括城堡投资集团、瑞银集团（自营交易集团）和纽伯格伯曼。他在Nexgen Spine的董事会任职，既有早期投资经验，又有战略经验，该董事会被Stryker Corporation收购。

他拥有密歇根大学的学士学位，并获得了哥伦比亚大学内外科医学院的医学博士学位。

Dr. Wilson Zhang is Co-Founder, President and Chief Executive Officer of Milu Labs, he formerly served as the Lead of Strategy and Corporate Development at Zhejiang Dian Diagnostics Co, one of the largest diagnostic labs in China and is publicly traded on the Shenzhen Stock Exchange. He has focused on establishing strategic collaborations with international and national IVD companies.

张博士已成功管理了整个诊断领域的多个中国入境项目，包括：

• 基础医学（个性化肿瘤伴随诊断）
• Ariosa Diagnostics（NIPT）
• Otogenetics Corporation（新一代测序）
• Biocore Co（基因检测）
• Metabolon Inc （代谢组学）
• 约翰霍普金斯医院（大学的全套诊断项目）

他还是上海ImmunoTech Bioscience公司的联合创始人和前首席技术官。此前，张博士曾在达特茅斯学院担任实验室经理和高级研究员，主要研究免疫学。他拥有上海交通大学医学院的医学博士学位，里维尔大学理学硕士学位，并进修了达特茅斯塔克商学院企业家课程。

Matthew G. Badalucco is Co-Founder, Chief Financial Officer and Chief Strategy Officer of Milu Labs. Mr. Badalucco has over a decade of investment experience across developed and emerging markets. He most recently was the Director of Investment Strategy at Catcha Group, one of the largest venture builders in Asia. There, he advised the CEO and charted the investment approach for the firm’s activities across the region by evaluating transactions across Malaysia, Indonesia, Thailand, Vietnam, Singapore, and the Philippines. In addition, he analyzed growth equity opportunities across China as Assistant Portfolio Manager at Sandell Asset Management and also worked in Dr. Chai’s team at Citadel Investment Group. He holds an A.B. with Honors from Dartmouth College, an M.B.A. from MIT, and an M.P.A. from Harvard University.

鲍引健博士作为商务拓展高管已在该领域工作了近30年。他的广泛经验包括医疗试剂的商业开发、材料消耗、实验室设备以及运营管理。

他曾担任WIPAK集团的中国全资子公司公共卫生产品总负责人，WIPAK集团是一家总部位于芬兰的全球性综合企业，在该集团中，他全权负责该类产品的进口计划、物流、许可证报批、市场、销售网络的建设和管理。

Previously, he was the Area Sales Manager of Shanghai Worldeast Commercial & Industrial Co; there, he fulfilled his role as the Sole Agent of Abbott Murex Diagnostic Products in China. Accordingly, he was responsible for channel management and sales of all Abbott Murex’s diagnostic products, including the automatic immunological analysis systems of DYNEX and Genesis; he was also managing the sales processes of other instruments such as the Fresenius blood transfusion system and the Abbott Determine rapid diagnostic products for CDC and CIQ.

包博士在上海交通大学医学院获得了医学博士学位。

Mark is an investment and finance professional with a wide range of experience in China. He was formerly a Vice President in the Asset Management division at Huarong International Financial Holdings Limited, a Hong Kong-listed licensed company (0993.HK), and a subsidiary of China Huarong Asset Management Co., Ltd. (2799.HK), one of the four asset management companies established by the Ministry of Finance of PRC. He conducted several equity and bond investments. He also coordinated establishment of funds in cooperation with reputative financial institutions.

Before that, Mark served as Business Development Manager and Investor Relations Manager at Hao Tian Development Group Limited, a Hong Kong-listed company (0474.HK). He focused on growing opportunities in China and contributed to investment, financing and operation in mineral, energy, healthcare and agricultural industries.

Mark holds a BCom in Finance from the Haskyne School of Business, University of Calgary, an M.S. in International Banking and Finance from Ling Nan University, and an Executive Diploma in Merger and Acquisition from HKU SPACE.

Ms. Ziyun Zhang is our Director of Corporate Affairs. She has extensive experience in managing the operations, strategic partnerships, and public relations of large, multinational companies.

Before joining Milu Labs, she had spent close to 30 years occupying leadership positions in Mcdonald’s China. Zhang pioneered the establishment of the first Ronald McDonald House in China, leading the Ronald McDonald House Charity project across the country. As a core aspect of this initiative, she coordinated with top-tier children’s hospitals and provided accommodation services for families in need; for example, she led the establishment of the Shanghai Ronald McDonald House and cooperated with the Shanghai Children Medicine Center in 2020. In addition, she directed McDonald’s Public Relations and Corporate Affairs departments in Beijing and China’s northern region from 1996 to 2014.

Ms. Zhang has a M.S. in Oral Medicine and a B.S. in Stomatology from Capital Medical University.

McElrath博士是哈佛医学院的教授，他在那里教授和研究了20多。他的研究重点是生物标志物流行病学，特别是早产和内分泌中断妊娠。他还在布莱根妇女医院执业，他的临床重点也是早产。他获得了密歇根大学学士学位;宾夕法尼亚大学的博士学位，哈佛医学院的医学博士学位。

Daniel W. Chan博士是约翰霍普金斯大学教授。他还担任约翰霍普金斯大学临床化学科主任、病理学核心实验室副主 任。他的研究重点是病理学，肿瘤学，放射学和泌尿学。他撰写了5本书，40本书章和300篇科学文章。

Chan博士曾多次获奖，包括MortonK.Schwartz癌症研究诊断奖，AlbertNichols实验医学战略创新奖，以及 Bernard Gerulat临床化学杰出成就奖。他获得了俄勒冈大学的学士学位;纽约州立大学布法罗分校的博士学位。

张博士是约翰霍普金斯大学病理学和肿瘤学副教授。他还担任约翰霍普金斯大学生物标记物发现和翻译中心的副主任。张博士的专长包括癌症、蛋白质组学、生物标志物开发、生物标志物发现、数学算法和生物统计学。

他与Chan博士合作开发了首个由FDA批准用于临床的蛋白质组生物标志物的体外诊断多元指数测定(IVDMIA)。他还发表了130多篇文章，重点关注生物标志物分析和生物信息学。

Gail Page是医疗保健和诊断行业的领导者。她曾担任Vermillion公司的总裁、首席执行官和主席。该公司是一家专注于开发和商业化新型多原子/MAAA血液检测解决方案的医疗健康公司。在Vermillion, 她与Quest Diagnostics建立了合作关系，并监管了首次FDA批准的、帮助诊断卵巢癌的血液检测的商品上市。

目前的董事会任命包括Sword Diagnostics，Inc.，NxPrenatal，Inc. 和Chembio (纳斯达克股票代码:CEMI)。她被任命为戴尔医学院Catalyst/德克萨斯大学董事会的首席商务顾问。佛罗里达大学理学学士;西北大学凯洛格管理学院高管教育。